Idiopathic Pulmonary Fibrosis Market Size 2025-2029
The idiopathic pulmonary fibrosis market size is forecast to increase by USD 1.61 billion, at a CAGR of 6.9% between 2024 and 2029.
- Increasing prevalence of respiratory diseases is the key driver of the idiopathic pulmonary fibrosis market. AstraZeneca Plc is a key player, offering idiopathic pulmonary fibrosis drugs such as saracatinib. This medication targets specific pathways involved in the progression of the disease, helping to slow its advancement. As the incidence of respiratory disorders rises, AstraZeneca's innovative treatments contribute to the growing demand for effective therapies in managing idiopathic pulmonary fibrosis. The respiratory drugs segment is expected to dominate the market, as these medications play a crucial role in managing symptoms and improving patient outcomes. Additionally, the medical diagnostics and patient monitoring segments are gaining traction, as early and accurate diagnosis of IPF is essential for effective treatment.
What will be the Size of the Idiopathic Pulmonary Fibrosis Market During the Forecast Period?
Request Free Sample
- The market encompasses diagnostic technologies, treatment options, and therapeutic approaches aimed at addressing this chronic lung disease characterized by impaired lung function and respiratory difficulties. The market's growth is driven by the increasing prevalence of IPF, which affects approximately 50,000 Americans, and the need for effective treatments to improve patient outcomes and enhance quality of life. Antifibrotic agents, such as pirfenidone and nintedanib, represent the primary therapeutic class, while immunosuppressants and targeted therapies are also under investigation. Diagnostic services, hospital pharmacies, retail pharmacies, and online providers play essential roles In the application of medical care for IPF patients. Multidisciplinary care teams in hospitals and clinics provide comprehensive treatment plans, ensuring the best possible care for those affected by this debilitating condition.
How is this Idiopathic Pulmonary Fibrosis Industry segmented and which is the largest segment?
The IPF industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion" for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.
- Route Of Administration
- Drug Class
- Systemic corticosteroids
- Immunosuppressants
- Tyrosine kinase inhibitors
- Anti-fibrotic agents
- Distribution Channel
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
- Geography
- North America
- Europe
- Asia
- Rest of World (ROW)
By Route Of Administration Insights
The oral segment is estimated to witness significant growth during the forecast period. The oral route of administration of drugs for most indications, including IPF, is one of the easiest, most convenient, and non-invasive methods of delivering medication to the body. Since it can be administered at home and is the most patient-friendly, this route is preferred by the majority of patients. Various dosage forms for oral medications are available, including tablets, capsules, and liquid solutions that can be ingested. The benefit of taking medications orally is that one can easily self-administer them and change the dosage if necessary. Additionally, compared to other routes of administration, oral medications have a longer half-life, which means that their effects may last longer.
Oral drug delivery also does away with the need for intravenous injections or inhalable drugs, which can be uncomfortable and challenging for some patients. The benefit of taking medications orally is that one can easily self-administer them and change the dosage if necessary. Additionally, compared to other routes of administration, oral medications have a longer half-life, which means that their effects may last longer. Oral drug delivery also does away with the need for intravenous injections or inhalable drugs, which can be uncomfortable and challenging for some patients.
Get a glance at the share of various segments. Request Free Sample
The oral segment was valued at USD 1.51 billion in 2019 and showed a gradual increase during the forecast period.
Regional Analysis
Europe is estimated to contribute 34% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
For more insights on the market share of various regions, Request Free Sample
Another region offering significant growth opportunities to companies is North America. The market in North America is projected to expand due to the increasing prevalence of chronic lung disorders, particularly IPF, among the geriatric population. Impaired lung function and respiratory difficulties associated with IPF necessitate diagnostic technologies and therapeutic approaches, driving market growth. Antifibrotic agents, such as pirfenidone and nintedanib, and immunosuppressants are common treatment options. Targeted therapies are emerging as promising trends in IPF treatment.
in addition, multidisciplinary care teams, including hospitals and clinics, pharmacies (hospital and retail), and online providers, provide medical care and diagnostic services for IPF patients. Reimbursement policies, economic development, and healthcare spending also influence market dynamics. Patient outcomes and quality of life are key considerations in IPF treatment, making personalized treatment options and telemedicine solutions increasingly important. The growing need for effective IPF management in outpatient settings underscores the importance of continued medical research and drug development for this chronic disorder.
Market Dynamics
Our researchers analyzed the data with 2024 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
What are the key market drivers leading to the rise In the adoption of Idiopathic Pulmonary Fibrosis (IPF) Industry?
Increasing prevalence of respiratory diseases is the key driver of the market.
- Idiopathic Pulmonary Fibrosis (IPF) is a chronic and progressive lung disorder that impairs lung function, resulting in respiratory difficulties and decreased quality of life. The global prevalence of IPF has been increasing, posing a significant challenge for healthcare providers and medical research. This debilitating disease affects thousands of people worldwide, with a higher incidence among the geriatric population. The primary cause of IPF is the scarring of lung tissue, which impedes the efficient transport of oxygen to the bloodstream. Diagnostic technologies play a crucial role in identifying IPF, and various diagnostic procedures, such as high-resolution computed tomography (HRCT) scans and lung function tests, are used to diagnose the condition.
- Once diagnosed, treatment options include antifibrotic agents like Pirfenidone and Nintedanib, immunosuppressants, and targeted therapies. The application of multidisciplinary care teams in outpatient settings is a promising trend in IPF treatment. These teams consist of healthcare professionals, including pulmonologists, nurses, and pharmacists, who work together to manage patient care. Reimbursement policies and economic development also impact patient footfall in hospitals and clinics, retail pharmacies, and online providers. Medical care and diagnostic services are essential components of IPF management. Patients require ongoing treatment and monitoring to manage their symptoms and improve their quality of life. The development of personalized treatment options and telemedicine solutions is a significant advancement in IPF care.
What are the market trends shaping the Idiopathic Pulmonary Fibrosis (IPF) Industry?
An increase in drug pipeline for IPF is the upcoming market trend.
- Idiopathic Pulmonary Fibrosis (IPF) is a chronic and debilitating lung disease characterized by impaired lung function and respiratory difficulties. The disease causes scarring of the lung tissue, leading to reduced lung capacity and breathing difficulties. The pipeline for IPF treatments is expanding due to the growing patient population and the need for effective therapeutic approaches. Antifibrotic agents, such as Pirfenidone (Esbriet), are currently used to slow down the progression of IPF. Immunosuppressants and targeted therapies are also under investigation. Diagnostic technologies play a crucial role In the accurate identification and diagnosis of IPF, and multidisciplinary care teams are essential for optimal patient outcomes and quality of life.
- The application of medical care, diagnostic services, and treatment in outpatient settings, hospitals, and clinics is vital for managing IPF. Reimbursement policies and economic development also impact patient footfall and healthcare spending. The geriatric population is disproportionately affected by IPF, making medical research and drug development a priority. Telemedicine solutions and diagnostic procedures are promising trends in IPF care, offering convenience and accessibility for patients. Overall, the IPF market is dynamic, with numerous diagnostic, treatment, and therapeutic approaches under development to improve patient outcomes and address the challenges of this chronic condition.
What challenges does the Idiopathic Pulmonary Fibrosis (IPF) Industry face during its growth?
The high cost of conducting clinical trials on IPF therapeutics is a key challenge affecting the industry growth.
- Idiopathic Pulmonary Fibrosis (IPF) is a chronic lung disease characterized by impaired lung function and respiratory difficulties. Diagnostic technologies play a crucial role in identifying IPF, and early diagnosis is essential for effective treatment. Treatment options for IPF include antifibrotic agents like Pirfenidone and Nintedanib, immunosuppressants, and targeted therapies. Multidisciplinary care teams in hospitals and clinics, outpatient settings, and pharmacies provide the application of medical care and diagnostic services. Patient footfall in hospital and retail pharmacies and online providers is increasing due to the need for ongoing treatment and management of IPF. Reimbursement policies and economic development influence healthcare spending on IPF treatment.
- The geriatric population is disproportionately affected by IPF, making medical research and drug development a promising trend. Financial barriers to accessing specialized medical care and diagnostic procedures can impact patient outcomes and quality of life. Telemedicine solutions and outpatient facilities offer potential solutions to address these challenges. Treatment for IPF is complex and costly due to the need for large patient populations and long-term follow-up periods in clinical trials. Ensuring the accuracy and relevance of research requires a focus on recruiting eligible IPF patients, making recruitment a significant challenge.
Exclusive Customer Landscape
The idiopathic pulmonary fibrosis (IPF) market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the idiopathic pulmonary fibrosis (IPF) market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Key Companies & Market Insights
Companies are implementing various strategies, such as strategic alliances, idiopathic pulmonary fibrosis (IPF) market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence In the industry.
AstraZeneca Plc - The company offers idiopathic pulmonary fibrosis drugs such as saracatinib.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
- Alembic Pharmaceuticals Ltd.
- Boehringer Ingelheim International GmbH
- Bristol Myers Squibb Co.
- Celix Pharma Ltd.
- Cipla Inc.
- Daewoong Pharmaceutical Co. Ltd.
- F. Hoffmann La Roche Ltd.
- FibroGen Inc.
- Galapagos NV
- Galecto Inc.
- GNI Group Ltd.
- Horizon Therapeutics Plc
- Intas Pharmaceuticals Ltd.
- Jubilant Pharmova Ltd.
- MediciNova Inc.
- Merck and Co. Inc.
- Mission Therapeutics
- Novartis AG
- SHIONOGI Co. Ltd.
- United Therapeutics Corp.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Research Analyst Overview
Idiopathic Pulmonary Fibrosis (IPF) is a chronic lung disorder that causes progressive fibrosis, or scarring, of the lungs, making it difficult for patients to breathe. Diagnosing IPF involves various technologies such as chest X-rays, CT scans, and pulmonary function tests, which help assess lung damage and determine treatment options. Treatment focuses on symptom management and slowing disease progression, with antifibrotic agents like pirfenidone and nintedanib being commonly used. Patients typically receive care from a multidisciplinary team of specialists, and treatment can be accessed in hospitals, clinics, and through telemedicine.
In addition, the economic burden of IPF is significant due to high diagnostic and treatment costs, with reimbursement policies playing a key role in patient access to care. The aging population is particularly affected, increasing outpatient visits, and telemedicine has emerged as a way to alleviate some of these pressures. Ongoing medical research is paving the way for personalized treatment approaches tailored to individual patient needs, optimizing outcomes. IPF requires a comprehensive approach to diagnosis, treatment, and care delivery.
|
Market Scope
|
|
Report Coverage
|
Details
|
|
Page number
|
218
|
|
Base year
|
2024
|
|
Historic period
|
2019-2023 |
|
Forecast period
|
2025-2029
|
|
Growth momentum & CAGR
|
Accelerate at a CAGR of 6.9%
|
|
Market growth 2025-2029
|
USD 1.61 billion
|
|
Market structure
|
Fragmented
|
|
YoY growth 2024-2025(%)
|
6.4
|
|
Key countries
|
US, Canada, China, Japan, Germany, UK, Mexico, France, Brazil, and Italy
|
|
Competitive landscape
|
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks
|
Request Free Sample
What are the Key Data Covered in this Idiopathic Pulmonary Fibrosis (IPF) Market Research and Growth Report?
- CAGR of the Idiopathic Pulmonary Fibrosis (IPF) industry during the forecast period
- Detailed information on factors that will drive the market growth and forecasting between 2025 and 2029
- Precise estimation of the size of the market and its contribution of the industry in focus to the parent market
- Accurate predictions about upcoming growth and trends and changes in consumer behaviour
- Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
- Thorough analysis of the market's competitive landscape and detailed information about companies
- Comprehensive analysis of factors that will challenge the idiopathic pulmonary fibrosis (ipf) market growth of industry companies
We can help! Our analysts can customize this idiopathic pulmonary fibrosis (ipf) market research report to meet your requirements.
Get in touch
1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by Route of Administration
- Executive Summary - Chart on Market Segmentation by Drug Class
- Executive Summary - Chart on Market Segmentation by Distribution Channel
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
- 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 2.2 Criticality of inputs and Factors of differentiation
- Overview on criticality of inputs and factors of differentiation
- 2.3 Factors of disruption
- Overview on factors of disruption
- 2.4 Impact of drivers and challenges
- Impact of drivers and challenges in 2024 and 2029
3 Market Landscape
- 3.1 Market ecosystem
- Parent Market
- Data Table on - Parent Market
- 3.2 Market characteristics
- Market characteristics analysis
4 Market Sizing
- 4.1 Market definition
- Offerings of companies included in the market definition
- 4.2 Market segment analysis
- 4.4 Market outlook: Forecast for 2024-2029
- Chart on Global - Market size and forecast 2024-2029 ($ million)
- Data Table on Global - Market size and forecast 2024-2029 ($ million)
- Chart on Global Market: Year-over-year growth 2024-2029 (%)
- Data Table on Global Market: Year-over-year growth 2024-2029 (%)
5 Historic Market Size
- 5.1 Global Idiopathic Pulmonary Fibrosis (IPF) Market 2019 - 2023
- Historic Market Size - Data Table on Global Idiopathic Pulmonary Fibrosis (IPF) Market 2019 - 2023 ($ million)
- 5.2 Route of Administration segment analysis 2019 - 2023
- Historic Market Size - Route of Administration Segment 2019 - 2023 ($ million)
- 5.3 Drug Class segment analysis 2019 - 2023
- Historic Market Size - Drug Class Segment 2019 - 2023 ($ million)
- 5.4 Distribution Channel segment analysis 2019 - 2023
- Historic Market Size - Distribution Channel Segment 2019 - 2023 ($ million)
- 5.5 Geography segment analysis 2019 - 2023
- Historic Market Size - Geography Segment 2019 - 2023 ($ million)
- 5.6 Country segment analysis 2019 - 2023
- Historic Market Size - Country Segment 2019 - 2023 ($ million)
6 Qualitative Analysis
- 6.1 Impact of AI on Global Idiopathic Pulmonary Fibrosis (IPF) Market
7 Five Forces Analysis
- 7.1 Five forces summary
- Five forces analysis - Comparison between 2024 and 2029
- 7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2024 and 2029
- 7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2024 and 2029
- 7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2024 and 2029
- 7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2024 and 2029
- 7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2024 and 2029
- 7.7 Market condition
- Chart on Market condition - Five forces 2024 and 2029
8 Market Segmentation by Route of Administration
- 8.1 Market segments
- Chart on Route of Administration - Market share 2024-2029 (%)
- Data Table on Route of Administration - Market share 2024-2029 (%)
- 8.2 Comparison by Route of Administration
- Chart on Comparison by Route of Administration
- Data Table on Comparison by Route of Administration
- 8.3 Oral - Market size and forecast 2024-2029
- Chart on Oral - Market size and forecast 2024-2029 ($ million)
- Data Table on Oral - Market size and forecast 2024-2029 ($ million)
- Chart on Oral - Year-over-year growth 2024-2029 (%)
- Data Table on Oral - Year-over-year growth 2024-2029 (%)
- 8.4 Parenteral - Market size and forecast 2024-2029
- Chart on Parenteral - Market size and forecast 2024-2029 ($ million)
- Data Table on Parenteral - Market size and forecast 2024-2029 ($ million)
- Chart on Parenteral - Year-over-year growth 2024-2029 (%)
- Data Table on Parenteral - Year-over-year growth 2024-2029 (%)
- 8.5 Market opportunity by Route of Administration
- Market opportunity by Route of Administration ($ million)
- Data Table on Market opportunity by Route of Administration ($ million)
9 Market Segmentation by Drug Class
- 9.1 Market segments
- Chart on Drug Class - Market share 2024-2029 (%)
- Data Table on Drug Class - Market share 2024-2029 (%)
- 9.2 Comparison by Drug Class
- Chart on Comparison by Drug Class
- Data Table on Comparison by Drug Class
- 9.3 Systemic corticosteroids - Market size and forecast 2024-2029
- Chart on Systemic corticosteroids - Market size and forecast 2024-2029 ($ million)
- Data Table on Systemic corticosteroids - Market size and forecast 2024-2029 ($ million)
- Chart on Systemic corticosteroids - Year-over-year growth 2024-2029 (%)
- Data Table on Systemic corticosteroids - Year-over-year growth 2024-2029 (%)
- 9.4 Immunosuppressants - Market size and forecast 2024-2029
- Chart on Immunosuppressants - Market size and forecast 2024-2029 ($ million)
- Data Table on Immunosuppressants - Market size and forecast 2024-2029 ($ million)
- Chart on Immunosuppressants - Year-over-year growth 2024-2029 (%)
- Data Table on Immunosuppressants - Year-over-year growth 2024-2029 (%)
- 9.5 Tyrosine kinase inhibitors - Market size and forecast 2024-2029
- Chart on Tyrosine kinase inhibitors - Market size and forecast 2024-2029 ($ million)
- Data Table on Tyrosine kinase inhibitors - Market size and forecast 2024-2029 ($ million)
- Chart on Tyrosine kinase inhibitors - Year-over-year growth 2024-2029 (%)
- Data Table on Tyrosine kinase inhibitors - Year-over-year growth 2024-2029 (%)
- 9.6 Anti-fibrotic agents - Market size and forecast 2024-2029
- Chart on Anti-fibrotic agents - Market size and forecast 2024-2029 ($ million)
- Data Table on Anti-fibrotic agents - Market size and forecast 2024-2029 ($ million)
- Chart on Anti-fibrotic agents - Year-over-year growth 2024-2029 (%)
- Data Table on Anti-fibrotic agents - Year-over-year growth 2024-2029 (%)
- 9.7 Market opportunity by Drug Class
- Market opportunity by Drug Class ($ million)
- Data Table on Market opportunity by Drug Class ($ million)
10 Market Segmentation by Distribution Channel
- 10.1 Market segments
- Chart on Distribution Channel - Market share 2024-2029 (%)
- Data Table on Distribution Channel - Market share 2024-2029 (%)
- 10.2 Comparison by Distribution Channel
- Chart on Comparison by Distribution Channel
- Data Table on Comparison by Distribution Channel
- 10.3 Hospital pharmacies - Market size and forecast 2024-2029
- Chart on Hospital pharmacies - Market size and forecast 2024-2029 ($ million)
- Data Table on Hospital pharmacies - Market size and forecast 2024-2029 ($ million)
- Chart on Hospital pharmacies - Year-over-year growth 2024-2029 (%)
- Data Table on Hospital pharmacies - Year-over-year growth 2024-2029 (%)
- 10.4 Retail pharmacies - Market size and forecast 2024-2029
- Chart on Retail pharmacies - Market size and forecast 2024-2029 ($ million)
- Data Table on Retail pharmacies - Market size and forecast 2024-2029 ($ million)
- Chart on Retail pharmacies - Year-over-year growth 2024-2029 (%)
- Data Table on Retail pharmacies - Year-over-year growth 2024-2029 (%)
- 10.5 Online pharmacies - Market size and forecast 2024-2029
- Chart on Online pharmacies - Market size and forecast 2024-2029 ($ million)
- Data Table on Online pharmacies - Market size and forecast 2024-2029 ($ million)
- Chart on Online pharmacies - Year-over-year growth 2024-2029 (%)
- Data Table on Online pharmacies - Year-over-year growth 2024-2029 (%)
- 10.6 Market opportunity by Distribution Channel
- Market opportunity by Distribution Channel ($ million)
- Data Table on Market opportunity by Distribution Channel ($ million)
11 Customer Landscape
- 11.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
12 Geographic Landscape
- 12.1 Geographic segmentation
- Chart on Market share by geography 2024-2029 (%)
- Data Table on Market share by geography 2024-2029 (%)
- 12.2 Geographic comparison
- Chart on Geographic comparison
- Data Table on Geographic comparison
- 12.3 North America - Market size and forecast 2024-2029
- Chart on North America - Market size and forecast 2024-2029 ($ million)
- Data Table on North America - Market size and forecast 2024-2029 ($ million)
- Chart on North America - Year-over-year growth 2024-2029 (%)
- Data Table on North America - Year-over-year growth 2024-2029 (%)
- 12.4 Europe - Market size and forecast 2024-2029
- Chart on Europe - Market size and forecast 2024-2029 ($ million)
- Data Table on Europe - Market size and forecast 2024-2029 ($ million)
- Chart on Europe - Year-over-year growth 2024-2029 (%)
- Data Table on Europe - Year-over-year growth 2024-2029 (%)
- 12.5 Asia - Market size and forecast 2024-2029
- Chart on Asia - Market size and forecast 2024-2029 ($ million)
- Data Table on Asia - Market size and forecast 2024-2029 ($ million)
- Chart on Asia - Year-over-year growth 2024-2029 (%)
- Data Table on Asia - Year-over-year growth 2024-2029 (%)
- 12.6 Rest of World (ROW) - Market size and forecast 2024-2029
- Chart on Rest of World (ROW) - Market size and forecast 2024-2029 ($ million)
- Data Table on Rest of World (ROW) - Market size and forecast 2024-2029 ($ million)
- Chart on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
- Data Table on Rest of World (ROW) - Year-over-year growth 2024-2029 (%)
- 12.7 US - Market size and forecast 2024-2029
- Chart on US - Market size and forecast 2024-2029 ($ million)
- Data Table on US - Market size and forecast 2024-2029 ($ million)
- Chart on US - Year-over-year growth 2024-2029 (%)
- Data Table on US - Year-over-year growth 2024-2029 (%)
- 12.8 Canada - Market size and forecast 2024-2029
- Chart on Canada - Market size and forecast 2024-2029 ($ million)
- Data Table on Canada - Market size and forecast 2024-2029 ($ million)
- Chart on Canada - Year-over-year growth 2024-2029 (%)
- Data Table on Canada - Year-over-year growth 2024-2029 (%)
- 12.9 China - Market size and forecast 2024-2029
- Chart on China - Market size and forecast 2024-2029 ($ million)
- Data Table on China - Market size and forecast 2024-2029 ($ million)
- Chart on China - Year-over-year growth 2024-2029 (%)
- Data Table on China - Year-over-year growth 2024-2029 (%)
- 12.10 Japan - Market size and forecast 2024-2029
- Chart on Japan - Market size and forecast 2024-2029 ($ million)
- Data Table on Japan - Market size and forecast 2024-2029 ($ million)
- Chart on Japan - Year-over-year growth 2024-2029 (%)
- Data Table on Japan - Year-over-year growth 2024-2029 (%)
- 12.11 Germany - Market size and forecast 2024-2029
- Chart on Germany - Market size and forecast 2024-2029 ($ million)
- Data Table on Germany - Market size and forecast 2024-2029 ($ million)
- Chart on Germany - Year-over-year growth 2024-2029 (%)
- Data Table on Germany - Year-over-year growth 2024-2029 (%)
- 12.12 UK - Market size and forecast 2024-2029
- Chart on UK - Market size and forecast 2024-2029 ($ million)
- Data Table on UK - Market size and forecast 2024-2029 ($ million)
- Chart on UK - Year-over-year growth 2024-2029 (%)
- Data Table on UK - Year-over-year growth 2024-2029 (%)
- 12.13 Mexico - Market size and forecast 2024-2029
- Chart on Mexico - Market size and forecast 2024-2029 ($ million)
- Data Table on Mexico - Market size and forecast 2024-2029 ($ million)
- Chart on Mexico - Year-over-year growth 2024-2029 (%)
- Data Table on Mexico - Year-over-year growth 2024-2029 (%)
- 12.14 France - Market size and forecast 2024-2029
- Chart on France - Market size and forecast 2024-2029 ($ million)
- Data Table on France - Market size and forecast 2024-2029 ($ million)
- Chart on France - Year-over-year growth 2024-2029 (%)
- Data Table on France - Year-over-year growth 2024-2029 (%)
- 12.15 Brazil - Market size and forecast 2024-2029
- Chart on Brazil - Market size and forecast 2024-2029 ($ million)
- Data Table on Brazil - Market size and forecast 2024-2029 ($ million)
- Chart on Brazil - Year-over-year growth 2024-2029 (%)
- Data Table on Brazil - Year-over-year growth 2024-2029 (%)
- 12.16 Italy - Market size and forecast 2024-2029
- Chart on Italy - Market size and forecast 2024-2029 ($ million)
- Data Table on Italy - Market size and forecast 2024-2029 ($ million)
- Chart on Italy - Year-over-year growth 2024-2029 (%)
- Data Table on Italy - Year-over-year growth 2024-2029 (%)
- 12.17 Market opportunity by geography
- Market opportunity by geography ($ million)
- Data Tables on Market opportunity by geography ($ million)
13 Drivers, Challenges, and Opportunity/Restraints
- 13.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2024 and 2029
- 13.4 Market opportunities/restraints
14 Competitive Landscape
- 14.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 14.3 Landscape disruption
- Overview on factors of disruption
- 14.4 Industry risks
- Impact of key risks on business
15 Competitive Analysis
- 15.2 Company ranking index
- 15.3 Market positioning of companies
- Matrix on companies position and classification
- 15.4 AstraZeneca Plc
- AstraZeneca Plc - Overview
- AstraZeneca Plc - Product / Service
- AstraZeneca Plc - Key news
- AstraZeneca Plc - Key offerings
- SWOT
- 15.5 Boehringer Ingelheim International GmbH
- Boehringer Ingelheim International GmbH - Overview
- Boehringer Ingelheim International GmbH - Product / Service
- Boehringer Ingelheim International GmbH - Key news
- Boehringer Ingelheim International GmbH - Key offerings
- SWOT
- 15.6 Bristol Myers Squibb Co.
- Bristol Myers Squibb Co. - Overview
- Bristol Myers Squibb Co. - Product / Service
- Bristol Myers Squibb Co. - Key news
- Bristol Myers Squibb Co. - Key offerings
- SWOT
- 15.7 Celix Pharma Ltd.
- Celix Pharma Ltd. - Overview
- Celix Pharma Ltd. - Product / Service
- Celix Pharma Ltd. - Key offerings
- SWOT
- 15.8 Cipla Inc.
- Cipla Inc. - Overview
- Cipla Inc. - Business segments
- Cipla Inc. - Key news
- Cipla Inc. - Key offerings
- Cipla Inc. - Segment focus
- SWOT
- 15.9 F. Hoffmann La Roche Ltd.
- F. Hoffmann La Roche Ltd. - Overview
- F. Hoffmann La Roche Ltd. - Business segments
- F. Hoffmann La Roche Ltd. - Key news
- F. Hoffmann La Roche Ltd. - Key offerings
- F. Hoffmann La Roche Ltd. - Segment focus
- SWOT
- 15.10 FibroGen Inc.
- FibroGen Inc. - Overview
- FibroGen Inc. - Product / Service
- FibroGen Inc. - Key offerings
- SWOT
- 15.11 Galapagos NV
- Galapagos NV - Overview
- Galapagos NV - Product / Service
- Galapagos NV - Key offerings
- SWOT
- 15.12 GNI Group Ltd.
- GNI Group Ltd. - Overview
- GNI Group Ltd. - Product / Service
- GNI Group Ltd. - Key offerings
- SWOT
- 15.13 Horizon Therapeutics Plc
- Horizon Therapeutics Plc - Overview
- Horizon Therapeutics Plc - Product / Service
- Horizon Therapeutics Plc - Key offerings
- SWOT
- 15.14 Jubilant Pharmova Ltd.
- Jubilant Pharmova Ltd. - Overview
- Jubilant Pharmova Ltd. - Business segments
- Jubilant Pharmova Ltd. - Key news
- Jubilant Pharmova Ltd. - Key offerings
- Jubilant Pharmova Ltd. - Segment focus
- SWOT
- 15.15 MediciNova Inc.
- MediciNova Inc. - Overview
- MediciNova Inc. - Product / Service
- MediciNova Inc. - Key offerings
- SWOT
- 15.16 Novartis AG
- Novartis AG - Overview
- Novartis AG - Business segments
- Novartis AG - Key news
- Novartis AG - Key offerings
- Novartis AG - Segment focus
- SWOT
- 15.17 SHIONOGI Co. Ltd.
- SHIONOGI Co. Ltd. - Overview
- SHIONOGI Co. Ltd. - Product / Service
- SHIONOGI Co. Ltd. - Key offerings
- SWOT
- 15.18 United Therapeutics Corp.
- United Therapeutics Corp. - Overview
- United Therapeutics Corp. - Product / Service
- United Therapeutics Corp. - Key offerings
- SWOT
16 Appendix
- 16.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 16.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 16.4 Research methodology
- 16.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 16.9 360 degree market analysis
- 360 degree market analysis
- 16.10 List of abbreviations
INFORMATION SOURCES
DATA ANALYSIS
REPORT WRITING
Get the report (PDF) sent to your email within minutes.
Complimentary full Excel data with your report purchase.
